- Home
- SUPN vs IHS Comparison
SUPN vs IHS Comparison
Compare SUPN & IHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- IHS
- Stock Information
- Founded
- SUPN 2005
- IHS 2001
- Country
- SUPN United States
- IHS United Kingdom
- Employees
- SUPN N/A
- IHS N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- IHS Telecommunications Equipment
- Sector
- SUPN Health Care
- IHS Telecommunications
- Exchange
- SUPN Nasdaq
- IHS Nasdaq
- Market Cap
- SUPN 1.7B
- IHS 1.6B
- IPO Year
- SUPN 2012
- IHS 2021
- Fundamental
- Price
- SUPN $31.70
- IHS $5.70
- Analyst Decision
- SUPN Hold
- IHS Strong Buy
- Analyst Count
- SUPN 2
- IHS 5
- Target Price
- SUPN $36.00
- IHS $7.60
- AVG Volume (30 Days)
- SUPN 420.5K
- IHS 883.8K
- Earning Date
- SUPN 05-06-2025
- IHS 05-16-2025
- Dividend Yield
- SUPN N/A
- IHS N/A
- EPS Growth
- SUPN N/A
- IHS N/A
- EPS
- SUPN 1.11
- IHS N/A
- Revenue
- SUPN $667,997,000.00
- IHS $1,711,225,000.00
- Revenue This Year
- SUPN N/A
- IHS $0.51
- Revenue Next Year
- SUPN $9.14
- IHS $6.34
- P/E Ratio
- SUPN $28.49
- IHS N/A
- Revenue Growth
- SUPN 11.82
- IHS N/A
- 52 Week Low
- SUPN $25.53
- IHS $2.44
- 52 Week High
- SUPN $40.28
- IHS $5.75
- Technical
- Relative Strength Index (RSI)
- SUPN 47.88
- IHS 67.44
- Support Level
- SUPN $29.16
- IHS $4.85
- Resistance Level
- SUPN $33.28
- IHS $6.00
- Average True Range (ATR)
- SUPN 1.19
- IHS 0.25
- MACD
- SUPN 0.02
- IHS 0.08
- Stochastic Oscillator
- SUPN 61.65
- IHS 77.36
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.